Alzheimer's Therapeutics Market 2020 To See Strong Growth Including Key Players - Eli Lilly and Company, Daiichi Sankyo F. Hoffmann-La Roche Ltd, Pfizer, Inc., Eisai Co

The Alzheimer's Therapeutics Market is expected to reach USD 12.43 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the growing pipeline drug development, investment in biomarkers for drug development which are expected to further accelerate the market growth globally. Based on statistics, increase in advanced diagnostics for early detection, along with more specific drug development, and emerging innovative diagnostics technologies are also some of the factors that are also helping to grow the size of the global market.

Download Sample Copy of this Report before you purchase free of cost! @ https://www.reportsanddata.com/sample-enquiry-form/1364

Companies considered and profiled in this market study

Eli Lilly and Company, Daiichi Sankyo F. Hoffmann-La Roche Ltd, Pfizer, Inc., Eisai Co., Ltd., Novartis AG, H. Lundbeck A/S, TauRx Therapeutics Ltd, Forest Laboratories, Inc., AC Immun, Johnson & Johnson, TauRx Pharmaceuticals Ltd, VTV Therapeutics

Alzheimer's disease (AD) is the most usual cause of dementia worldwide. The study of this disease is multifactorial, and pathophysiology is also complicated. According to several types of research, an exponential rise in the number of cases of AD, highlighting the need for developing an effective treatment. AD also imposes a tremendous emotional and financial trouble to the patient's family and society. The disease has been studied for more than a century, but memantine and acetylcholinesterase inhibitors are the only drugs currently recommended for its management. These drugs provide significant improvement alone but do less to change the disease process. The significant penetration into the molecular and cellular pathomechanism in AD over the previous few decades has given us considerable progress in the understanding of the disease. Several novel strategies that seek to revise the disease process have been developed. The notable developments in this direction are the tau-based and amyloid therapeutics, which could hold the key to treatment of AD shortly.

North America market for Alzheimer's Therapeutics accounts for the largest share of 29.30% in 2018. Due to the presence of advanced healthcare facilities and infrastructure in developed countries, such as the U.S. Moreover, the high buying power for expensive drugs and compensation policies are the drivers projected to promote the market demand.

For the purpose of this study, Reports and Data have segmented the global Alzheimer's Therapeutics Market on the basis of Therapeutics, End-User, Diagnostics Type and Region:

Therapeutics Outlook (Revenue, USD Million; 2016-2026)
Cholinesterase inhibitors
Pipeline Drugs
NMDA receptor antagonist

End User Outlook (Revenue, USD Million; 2016-2026)
Hospital Pharmacies
Retail Pharmacies
e-Commerce

Grab Your Report at an Impressive Discount! Please Click Here @ https://www.reportsanddata.com/discount-enquiry-form/1364

Diagnostics Type Outlook (Revenue, USD Million; 2016-2026)
Computed tomography (CT) scan
Magnetic resonance imaging (MRI)
Lumbar puncture test
Electroencephalography (EEG)
Others

Regional Outlook (Revenue, USD Million; 2016-2026)
North America
Europe
Asia Pacific
South-east Asia
Latin America
MEA

Further key findings from the report suggest

1. Alzheimer's is a kind of dementia, which affects thinking, behavior, and memory of the patient. The progression of the disease is moderate, and it diminishes neurons associated with the learning part of the cerebrum. It is the most common and the most significant form of dementia (more than 60%), which can be observed in people of age between 65 and over.

2. Many researches are being conducted to promote treatment concentrated on the role of beta-amyloid in Alzheimer's disease. The artificial joints are designed to replicate the movement of a typical, healthy joint.

3. Cholinesterase inhibitors therapeutics accounts for the largest share of 38.85% in 2018. It can also improve neuropsychiatric symptoms, such as depression or agitation.

4. Generally prescribed cholinesterase inhibitors are galantamine (Razadyne), donepezil (Aricept), and rivastigmine (Exelon).

5. CT scans often can reveal specific changes that are characteristic of Alzheimer's disease in its succeeding stages. These changes include widened indentations in the tissues, a reduction in the size of the brain (atrophy), and expansion of the fluid-filled chambers called cerebral ventricles.

6. CT scan diagnostic type is expected to reach USD 4.95 billion by 2026. CT (computed tomography) scan is a procedure in which various X-rays of the body are examined from several angles in a short period.

7. CT imaging generates the images by estimating how quickly the body and organs receive the X-rays.

8. The pipeline drugs sector accounts for a market share of 31.15% in 2018. The presence and advancement of pipeline drugs, such as LMTX by TauRx Pharmaceuticals Ltd., are anticipated to have a substantial positive impact on the growth of this industry.

To Buy This Report, Click Here @ https://www.reportsanddata.com/checkout-form/1364

Key selling points of this research study

1. The study gives an in-depth evaluation of the evolving competitive scenario that gives the reader/client a competitive edge.

2. It offers a holistic view of all critical aspects boosting or limiting the growth of the sector

3. The market intelligence report derives an eight-year forecast, including historical, contemporary, and potential market prospects, projecting the estimated progress of the market.

4. It aids informed decision-making by offering an exhaustive database of the pivotal market segments and sub-segments.

Contact Us:

John Watson
Head of Business Development
Reports and Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.